Table 6. Mean values (M ± SD) of malondialdehyde and TAC in piperazine treated group (n = 20) and D_oraTG (n = 20).

Groups	Follow up period	MDA (μmol/l) (0.86 ± 0.15)1 or (1.21 ± 0.29)2 or (6.98 ± 0.98)3	TAC (mmol/l) (0.81 ± 0.04)2
PipTG	Day 0a	24.81 ± 5.20	0.024 ± 0.012
	Day 7	18.701 ± 3.43b	0.060 ± 0.021b
	Day 14	15.03 ± 2.93b	0.120 ± 0.066b
	Day 21	9.54 ± 2.00b	0.215 ± 0.083b
	Day 28	5.56 ± 0.72b	0.318 ± 0.035b
DoraTG	Day 0a	20.93 ± 2.59	0.035 ± 0.012
	Day 7	9.94 ± 2.08c,d	0.073 ± 0.024c,e
	Day 14	8.20 ± 2.56c,d	0.217 ± 0.038c,e
	Day 21	6.24 ± 2.22c,d	0.316 ± 0.024c,e
	Day 28	3.08 ± 0.81c,d	0.376 ± 0.024c,e

Reference values according to Deger et al. (2009), Hassanpour (2013), Onmaz et al. (2011).

P_ipTG = piperazine treated group; D_oraTG = doramectin treated group; MDA = malondialdehyde; TAC = total antioxidant capacity.

^aTreatment day.

^bSignificant when the values at each sampling day (7, 14, 21 or 28) compared with the value day 0 in P_ipTG (p < 0.05).

^cSignificant when the values at each sampling day (7, 14, 21 or 28) compared with the value at day 0 in D_oraTG (p < 0.05).

^dSignificant when the value of MDA in DoraTG compared with those in P_ipTG in each sampling day (0, 7, 14, 21 and 28) (p < 0.05).

^eSignificant when the value of TAC in DoraTG compared with those in P_ipTG in each sampling day (0, 7, 14, 21 and 28) (p < 0.05).